CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control (Q36927210)

17 August 2017

CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control (English)

1 reference

17 August 2017

5

Wolfgang Sadee

1 reference

17 August 2017

Joseph Paul Kitzmiller

1

1 reference

17 August 2017

Danielle M Sullivan

2

1 reference

17 August 2017

Mitchell A Phelps

3

1 reference

17 August 2017

Danxin Wang

4

1 reference

17 August 2017

1 January 2013

1 reference

Drug Metabolism and Drug Interactions

17 August 2017

1 reference

17 August 2017

28

1 reference

17 August 2017

1

1 reference

17 August 2017

59-63

1 reference

Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

Combinatorial pharmacogenetics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

Genetic variability in CYP3A5 and its possible consequences.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681953

The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients.

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23314529

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23314529

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1515/DMDI-2012-0031

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

23314529

1 reference